|
|
 |
 |
|
|
UMN Pharma
Inc. is a pharmaceutical company dedicated to developing
innovative pharmaceutical products that will satisfy
unmet medical needs; our most important mission is to
provide good candidates having proof of concept in clinical
stage to big Pharma. Our core competencies reside in
utilizing our significant experience in the pharmaceutical
industry to generate time-efficient, focused development
plans followed by rapid preclinical and clinical development
to meet international regulatory specifications. We
have a pipeline of diverse novel small molecule and
protein drug candidates targeting large (cancer and
diabetes) and relatively small (pancreatitis and muscular
dystrophy) pharmaceutical markets that are seriously
underserved by existing therapeutics, and influenza
vaccine:
|
1)
|
UMN-01, an anti-cancer
drug, is a first-in-class GRP78 down-regulator specifically
under the condition of glucose starvation, which is well
seen in various solid tumors. We are currently conducting
the preclinical studies, and the clinical study will be
started in late 2007.
|
|
| 2) |
UMN-02, for the treatment
of pancreatitis, is a drug repurposing project using an
already approved drug and it is our original project.
Since this strategy is known as an effective way to discover
a late stage project, many companies are taking this strategy.
UMN-02 is under preparation for the clinical study that
will be started in the US in early 2007 after getting
the clinical POC in Japan in 2006. |
3)
|
UMN-03, for muscular dystrophy,
diabetes and obesity, is a myostatin-inhibiting fusion
protein of a part of specific protein and the Fc portion
of IgG. We have signed a research licensing agreement
with Crucell/DSM to manufacture UMN-03. After finishing
the manufacture of the clinical sample, the clinical study
will be started in 2008. |
| 4) |
UMN-05, influenza vaccine,
is an in-licensed product from Protein Sciences Corporation
(PSC). The PSC’s proprietary product, FluBlØk™,
is under clinical development and will be launched in
2007. We will start the preclinical study in 2006 and
the clinical study in early 2007. |
| We have raised
approximately $28.5 million from 24 prominent investors
including Pacific Rim Ventures, Nomura Research & Advisory,
NIF SMBC Ventures and ASTEC. |
|
|
 |
|
|
| Company
Name |
UMN
Pharma Inc. |
| Incorporated |
April 20,
2004 |
| President |
Shuichi Kanazashi, M.D.,Ph.D. |
| Akita
office |
901, 3-1-9,
Nakadori, Akita-city, Akita 010-0001 |
| |
TEL +81-18-884-0577 |
| |
FAX +81-18-884-0578 |
| Tokyo
head office |
Kanenaka Bldg. 4th FL, 1-15-8,
Jinnan, Shibuya-ku, Tokyo 150-0041, Japan |
| |
TEL +81-3-5728-5420 |
| |
FAX +81-3-5728-5421 |
| |
Contact
Form |
| Access
Map |
|
| US
liaison |
Jonathan M. Drutz
Director of Business Development |
|
101 Oak
Tree Drive, Chapel Hill, NC 27517, USA |
| |
TEL 919-960-3513 |
| |
FAX 919-942-4501 |
| Akita
labo. |
Molecular
Medicine Laboratory, Bioscience Education and Research
Center, Akita University, 1-1-1, Hondo, Akita, Akita
010-8543, Japan |
| |
TEL +81-18-884-6280 |
| |
FAX +81-18-884-6280 |
|
|
|
 |
|
|
| Apr. |
2004 |
Incorporated |
| Aug. |
2004 |
UMN-01:
option agreement with Toudai TLO Ltd. |
| Nov. |
2004 |
Series
A round (first tranche), $ 0.9 million |
| Feb. |
2005 |
Mr. Kashihara appointed President and CEO |
| Mar. |
2005 |
UMN-03:
option agreement with Techno Network Shikoku Co.,Ltd. |
| Apr. |
2005 |
UMN-02:
patent filed |
| Jun. |
2005 |
UMN-01:
license agreement with Toudai TLO Ltd. |
| Jul. |
2005 |
relocation
of Tokyo office |
| Jul. |
2005 |
Series
A round (second tranche), $ 1.0 million |
| Oct. |
2005 |
Series
B-1 round, $ 1.1 million |
| Feb. |
2006 |
Series
B-2 round, $ 7.5 million |
| Feb. |
2006 |
UMN-03:
license agreement with Techno Network Shikoku Co.,Ltd. |
| Mar. |
2006 |
UMN-03:
license agreement with Crucell and DSM Biologics |
| Jun. |
2006 |
Renamed
Tokyo office as Tokyo head office |
| Jul. |
2006 |
Relocation
of Tokyo head office |
| Aug. |
2006 |
UMN-05:
license agreement with Protein Sciences Corporation |
| Oct. |
2006 |
Establishment
of Akita laboratory |
| Nov. |
2006 |
Establishment
of US office |
| Nov. |
2006 |
UMN-03:
Biopharmaceutical Manufacturing Agreement with DSM
Biologics |
| Feb. |
2007 |
Series C round, $ 18.9 million |
| Nov. |
2007 |
Dr. Kanazashi appointed President and CEO |
|
| |
|
|
|
|
